Latest Conference Coverage

Pimavanserin Reduces Dementia-Related Psychosis Symptoms

Additional data presented at AAIC 2020 shows the clinical benefit pimavanserin has on dementia-related psychosis while the agent awaits a PDUFA date of April 3, 2021.

P-Tau217 May Detect Alzheimer Disease, Brain Amyloidosis, Tauopathy

The performance of p-tau217 was similar to significantly more costly methods, such as PET imaging and measuring cerebrospinal fluid biomarkers.

Influenza, Pneumonia Vaccination May Reduce Alzheimer Disease Risk

A trio of studies presented at AAIC 2020 suggest that consistently vaccinations for influenza and pneumonia may reduce the incidence of Alzheimer later in life, as well as mortality for older adults.

Matthew Robbins, MD: Headaches Associated With COVID-19

The director of the Neurology Residency Program at Weill Cornell Medicine highlighted some of the differences in types of headaches that patients with COVID-19 experience, as well as overall takeaways from the pandemic itself.

Fred Cohen, MD: OnabotulinumtoxinA and CGRP Combination Treatment

The internal medicine resident physician at Montefiore Health System provided an overview of the study he and colleagues conducted on patients using onabotulinumtoxinA and CGRP agents in tandem.

Kathleen Digre, MD, on Eye Pain and Photophobia in Migraine

Despite its ranking as a "most bothersome symptom" among migraineurs, eye pain and photophobia often go ignored or under-treated in the headache clinic.

Roger Cady, MD: Rapid Effect of Eptinezumab on Migraine

The head of Neurology Medical at Lundbeck Seattle Biopharmaceuticals offers perspective on the findings and what impact eptinezumab may have on migraine care.

Total Migraine Pain Burden Reduced With Galcanezumab in Post-Hoc Analysis

Treatment with galcanezumab (Emgality; Eli Lilly) was associated with improvements in total pain burden for patients with both chronic and episodic migraine compared to placebo groups.

Matthew Robbins, MD: Residency During COVID-19

The director of the Neurology Residency Program at Weill Cornell Medicine provided insight on the experience residents have had during the COVID-19 pandemic and how it has shaped them for the future.

Chia-Chun Chiang, MD: Collecting Real-World Data Following FDA Approvals

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed the importance of further studies of FDA approved medications in different patient populations.

Long-Term Safety Study Confirms Efficacy of ADAM Zolmitriptan in Acute Migraine

The FDA accepted an NDA for Zosano’s ADAM zolmitriptan (Qytripta) in the acute treatment of migraine in early March, with a PDUFA date set for mid-October 2020.

Chia-Chun Chiang, MD: Variations in FDA Approved Migraine Medications

The neurologist at Mayo Clinic in Phoenix, Arizona, discussed the growing variety of treatment options and the progress the migraine community has made on the management of this disease.

Migraine Care During a Pandemic: Takeaways for the Future

In part 2 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, describes the lessons he and his residents have learned during the COVID-19 pandemic and how they'll impact the future of care.

Chia-Chun Chiang, MD: Comparing Ubrogepant Study Results

The neurologist at Mayo Clinic in Phoenix, Arizona, detailed whether her and colleagues recent study results on ubrogepant aligned with previous study findings.

Fred Cohen, MD: Combining CGRPs and OnabotulinumtoxinA for Migraine Prevention

The internal medicine resident physician at Montefiore Health System offers insight into the combined use of CGRP medications and Botox to optimize migraine prevention in patients who have inadequate response with Botox alone.

Neurology and COVID-19: Adapting Specialty Care During the Pandemic

In Part 1 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, shares his experience caring for headache patients in the epicenter of the coronavirus 2019 pandemic.

Gilbert L'Italien, PhD: The Economic Impact of MIDAS Disability Grades in Migraine

The senior VP of Global Health Economics and Outcomes Research and Epidemiology at Biohaven Pharmaceuticals discussed the findings from a poster presentation on the economic impact of migraine disability at AHS 2020.

High Frequency Episodic Migraine Has Similar Burden to Low Frequency Chronic Migraine

Treatment needs of those with high frequency episodic migraine may be similar to those with low frequency chronic migraine.

Ubrogepant Effective for Migraine Patients With Insufficient Triptan Response

The recently approved Allergan agent reported lower rates of functional disability and better overall satisfaction with treatment, as well as similar success for those who did not experience efficacy with triptans.

Matthew Robbins, MD: Experience Adjusting to COVID-19 in Migraine Care

The director of the Neurology Residency Program at Weill Cornell Medicine details his first-hand experience working in the epicenter of the COVID-19 pandemic and how his department adapted.

The Long-Term Impact of Addressing Gender Norms for Men With MS

In Part 2 of this interview, Bryan Davis, PsyD, MS, clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS, details the impact that conversations about masculinity norms in MS can have on future trials and care.

Migraine History Pre-Concussion Linked to Worse Symptoms Post-Injury

Patients with pre-concussion migraines that occurred at a rate of >1 per month had a greater number of concussion symptoms and burden over 12 weeks.

Atogepant Proves Safe Without ALT Elevation in Healthy Participants

Data presented at AHS 2020 suggest that 170-mg oral atogepant (Allergan) was both safe and well-tolerated, setting the stage the continued development in migraine prevention.

Celecoxib Oral Solution Offers Effective Alternative to Triptans in Acute Migraine

Data from a pair of phase 3 studies suggest that the recently approved celecoxib oral solution (Elyxyb; Dr. Reddy’s Laboratories) offers safe and effective acute treatment of episodic migraine.

Jessica Ailani, MD, FAHS: The Staying Power of Telemedicine in Headache

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed how this year has proved that telemedicine is likely here to stay.

OnabotulinumtoxinA Proves Safe as Migraine Treatment for Pregnant Women

Infants born to pregnant women with chronic migraine who received treatment with onabotulinumtoxinA did not show any physical, intellectual, or social disabilities.

Migraine With Aura Linked to High Risk of Dementia in Later Life

The results help to better understand the unique risk profiles of people with different subtypes of migraine.

Bryan Davis, PsyD, MS: Future Discussion on Masculinity Norms in MS

The clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research at Cleveland Clinic details the interventions for men with MS and how the study can change the discussion on masculinity norms.

Youth With Migraine Improve Post-Preventive Treatment Regardless of Therapy Continuation

Results from the CHAMP trial of adolescents and children with migraine add to the already active and ongoing discussion surrounding the use of preventives in this population.

Erenumab Shows Sustainable Efficacy in Refractory Episodic Migraine

Over a 2-year stretch, change in monthly migraine days from the double-blind treatment period baseline was sustained in those treated with erenumab.